KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Staar Surgical (STAA) Share-based Compensation (2016 - 2026)

Staar Surgical (STAA) has disclosed Share-based Compensation for 17 consecutive years, with $8.6 million as the latest value for Q1 2026.

  • For the quarter ending Q1 2026, Share-based Compensation rose 84.47% year-over-year to $8.6 million, compared with a TTM value of $30.6 million through Jan 2026, up 12.41%, and an annual FY2026 reading of $30.6 million, up 12.41% over the prior year.
  • Share-based Compensation was $8.6 million for Q1 2026 at Staar Surgical, up from $8.2 million in the prior quarter.
  • Across five years, Share-based Compensation topped out at $9.0 million in Q2 2024 and bottomed at $182000.0 in Q4 2023.
  • Average Share-based Compensation over 5 years is $6.4 million, with a median of $6.2 million recorded in 2023.
  • The sharpest move saw Share-based Compensation plummeted 96.36% in 2023, then soared 2465.38% in 2024.
  • Year by year, Share-based Compensation stood at $5.0 million in 2022, then tumbled by 96.36% to $182000.0 in 2023, then skyrocketed by 2465.38% to $4.7 million in 2024, then soared by 74.73% to $8.2 million in 2025, then increased by 5.58% to $8.6 million in 2026.
  • Business Quant data shows Share-based Compensation for STAA at $8.6 million in Q1 2026, $8.2 million in Q3 2025, and $7.8 million in Q2 2025.